Please login to the form below

Not currently logged in
Email:
Password:

Shire boosts orphan drug pipeline with Meritage Pharma deal

Firm will also acquire global rights to Meritage’s phase III OBS compound

Shire BasingstokeShire has obtained the rights to privately held Meritage Pharma, in connection with its acquisition of ViroPharma in late 2013.

As part of the acquisition, Shire has acquired the global rights to Meritage's phase III compound Oral Budesonide Suspension (OBS) for the treatment of adolescents and adults with eosinophilic esophagitis (EoE), a rare chronic inflammatory gastrointestinal (GI) disease.

Philip Vickers, head of research and development at Shire, commented: “Shire's pipeline and strategic focus on rare diseases is further strengthened with the acquisition of Meritage, which also complements our strong GI capabilities.

“Adding this phase III-ready compound to our late-stage portfolio will allow us to leverage our expertise to further develop this important therapy that, if approved, will give hope to patients living with eosinophilic esophagitis.”

The deal includes a $70m upfront fee, in addition to contingent payments based on the success of unspecified development and regulatory milestones.

The acquisition was made possible in conjunction with the firm's $4.2bn takeover of ViroPharma in November 2013, further expanding Shire's portfolio of rare disease therapies.

Meritage president and CEO, Elaine Phillips, added: “The acquisition of Meritage by Shire, a global biotechnology company with GI and rare disease expertise, may benefit physicians and patients by helping develop OBS to potentially become the first approved treatment in the US indicated for this often disabling disease.”

Meritage Pharma was founded in 2008, with a specialised focus on the development of prescription products for the treatment of gastrointestinal and atopic diseases.

Article by
Kirstie Pickering

26th February 2015

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
CSafe Global

CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...

Latest intelligence

patient diversity buckland
Patient diversity in clinical trials needs to be centre stage
By Danny Buckland...
Why empathy in digital patient recruitment is vital
This is where empathy mapping can be incredibly effective....
Top 10 ways that Medical Affairs teams can leverage the Impetus InSite Platform®
Some of the most popular and innovative ways of using our cutting-edge asynchronous and synchronous virtual tools for Medical Affairs teams....